Persistent fetal circulation syndrome
diseaseOn this page
Also known as persistent fetal circulationpersistent foetal circulationpersistent pulmonary hypertension of the newbornPPHN
Summary
Persistent fetal circulation syndrome (MONDO:0022430) is a disease and 30 clinical trials. Top therapeutic interventions include milrinone, bosentan, and nitrogen. A subtype of congenital anomaly of cardiovascular system — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 30
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | persistent fetal circulation syndrome |
| Mondo ID | MONDO:0022430 |
| EFO | EFO:1001103 |
| MeSH | D010547 |
| ICD-10-CM | P29.3 |
| ICD-11 | 346808536 |
| NCIT | C85006 |
| SNOMED CT | 206597007, 233815004, 35604006 |
| UMLS | C0031190 |
| MedGen | 45824 |
| GARD | 0027905 |
| Is cancer (heuristic) | no |
Also known as: persistent fetal circulation · persistent foetal circulation · persistent pulmonary hypertension of the newborn · PPHN
Disease family
This is a subtype of congenital anomaly of cardiovascular system. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › congenital anomaly of cardiovascular system › persistent fetal circulation syndrome
Related subtypes (4): venous hemangioma, congenital heart disease, congenital heart malformation, congenital arteriovenous fistula
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Bosentan | Phase 3 (in late-stage trials) |
| Nitric Oxide | Phase 3 (in late-stage trials) |
| Sildenafil | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Treprostinil.
Clinical trials & evidence
Clinical trials
Clinical trials: 30.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 16 |
| PHASE3 | 5 |
| PHASE2 | 4 |
| PHASE4 | 2 |
| PHASE1/PHASE2 | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00732537 | PHASE4 | COMPLETED | Inhaled Nitric Oxide by Oxygen Hood in Neonates |
| NCT01891500 | PHASE4 | WITHDRAWN | Early iNO for Oxidative Stress, Vascular Tone and Inflammation in Babies With Hypoxic Respiratory Failure |
| NCT05527704 | PHASE3 | ACTIVE_NOT_RECRUITING | the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial) |
| NCT00005773 | PHASE3 | TERMINATED | Early Inhaled Nitric Oxide for Respiratory Failure in Newborns |
| NCT00005776 | PHASE3 | TERMINATED | Inhaled Nitric Oxide Study for Respiratory Failure in Newborns |
| NCT01389856 | PHASE3 | TERMINATED | Persistent Pulmonary Hypertension of the Newborn |
| NCT01558466 | PHASE3 | UNKNOWN | Sildenofil in Persistent Pulmonary Hypertension in Newborns |
| NCT01069861 | PHASE2 | TERMINATED | Study To Investigate Safety And Efficacy Of Sildenafil In The Newborns With Persistent Pulmonary Hypertension (PPHN) |
| NCT01360671 | PHASE2 | WITHDRAWN | IV Sildenafil Persistent Pulmonary Hypertension Of The Newborn |
| NCT02261883 | PHASE2 | TERMINATED | Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn |
| NCT02951130 | PHASE2 | COMPLETED | Milrinone in Congenital Diaphragmatic Hernia |
| NCT04328636 | PHASE1/PHASE2 | COMPLETED | Nebulized MgSO4 in Persistent Pulmonary Hypertension of Newborn |
| NCT06860399 | PHASE1/PHASE2 | COMPLETED | Vardenafil Vs Sildenafil for the Treatment of Pulmonary Hypertension of the Newborn |
| NCT01670136 | PHASE1 | COMPLETED | Pharmacokinetics of Sildenafil in Premature Infants |
| NCT00710177 | Not specified | RECRUITING | PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn |
| NCT04938167 | Not specified | ACTIVE_NOT_RECRUITING | Preductal Oxygen Saturation Target in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure or Pulmonary Hypertension |
| NCT06832163 | Not specified | RECRUITING | Close Loop Smart Weaning for INO With PPHN |
| NCT00005323 | Not specified | COMPLETED | Epidemiology of Persistent Pulmonary Hypertension of the Newborn - SCOR in Lung Biology and Diseases in Infants and Children |
| NCT00005497 | Not specified | COMPLETED | Risk Factors for Pulmonary Hypertension of the Newborn |
| NCT00371241 | Not specified | COMPLETED | Antibody Secreting Cell and Cyotokine Profiles in Neonates on ECMO |
| NCT01088997 | Not specified | TERMINATED | Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn |
| NCT01203423 | Not specified | COMPLETED | Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study |
| NCT02380040 | Not specified | UNKNOWN | Plethismographic Perfusion Index in Neonates |
| NCT02940327 | Not specified | COMPLETED | Markers of Inflammation and Lung Recovery in ECMO Patients for PPHN |
| NCT03499418 | Not specified | WITHDRAWN | Evaluation of the Prevalence of Persistent Pulmonary Hypertension in Neonates |
| NCT04379180 | Not specified | UNKNOWN | Population Pharmacokinetics and Dosage Individualization of Oral Pulmonary Vasodilators in PPHN |
| NCT04841070 | Not specified | COMPLETED | NEURodevelopmental Outcome After Persistent Pulmonary Hypertension Of the Newborn |
| NCT05741229 | Not specified | COMPLETED | The Effect Of Nebulizied Nitroglycerin As An Adjuvant Therapy For Persistent Pulmonary Hypertension Of Newborns |
| NCT06043635 | Not specified | WITHDRAWN | Predictors of Inhaled Nitric Oxide Responsiveness in Patients With PPHN |
| NCT06562036 | Not specified | COMPLETED | Efficacy of Milrinone With Sildenafil in Persistent Pulmonary Hypertension in Children |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| MILRINONE | 4 | 3 |
| BOSENTAN | 4 | 2 |
| NITROGEN | 4 | 1 |
| OXYGEN | 4 | 1 |
| VARDENAFIL | 4 | 1 |
| CHEMBL168949 | 0 | 1 |
| CHEMBL3769434 | 0 | 1 |
Related Atlas pages
- Drugs: Milrinone, Bosentan, Nitrogen, Oxygen, Vardenafil